Detalhe da pesquisa
1.
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
PLoS Med
; 17(10): e1003348, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33125391
2.
Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.
BMC Med
; 18(1): 298, 2020 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33143745
3.
Prediction of natalizumab anti-drug antibodies persistency.
Mult Scler
; 25(3): 392-398, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29336205
4.
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
Mult Scler
; 24(9): 1224-1233, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28762877
5.
Smoking and risk of treatment-induced neutralizing antibodies to interferon ß-1a.
Mult Scler
; 20(4): 445-50, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23924603
6.
Short report: Real-life analysis of the occurrence of persistent, transient, and fluctuating positive titres of neutralizing anti-drug antibodies in multiple sclerosis patients treated with interferon beta.
Mult Scler Relat Disord
; 63: 103815, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35508100
7.
Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis.
J Neuroimmunol
; 370: 577932, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35853357
8.
First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis.
Arthritis Res Ther
; 23(1): 211, 2021 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34389040
9.
Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier.
Front Immunol
; 11: 1365, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32793189
10.
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
J Neuroimmunol
; 326: 19-27, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30447419
11.
Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.
Front Neurol
; 8: 305, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28729851
12.
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
PLoS One
; 12(2): e0170395, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28170401
13.
Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.
J Immunol Methods
; 430: 1-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26779831
14.
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
PLoS One
; 11(11): e0162752, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27806057
15.
Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point.
J Interferon Cytokine Res
; 34(7): 498-504, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24444338
16.
The case for measuring anti-drug antibodies in people with multiple sclerosis.
Expert Rev Clin Immunol
; 10(6): 697-9, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24780058
17.
Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.
PLoS One
; 9(3): e90479, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24608124